200 related articles for article (PubMed ID: 21865577)
21. Proton spectroscopy in Alzheimer's disease and cognitive impairment no dementia: a community-based study.
Azevedo D; Tatsch M; Hototian SR; Bazzarella MC; Castro CC; Bottino CM
Dement Geriatr Cogn Disord; 2008; 25(6):491-500. PubMed ID: 18441524
[TBL] [Abstract][Full Text] [Related]
22. Association of 1H-MR spectroscopy and cerebrospinal fluid biomarkers in Alzheimer's disease: diverging behavior at three different brain regions.
Bittner DM; Heinze HJ; Kaufmann J
J Alzheimers Dis; 2013; 36(1):155-63. PubMed ID: 23579327
[TBL] [Abstract][Full Text] [Related]
23. Brain metabolites and cognitive function among older depressed and healthy individuals using 2D MR spectroscopy.
Elderkin-Thompson V; Thomas MA; Binesh N; Mintz J; Haroon E; Dunkin JJ; Kumar A
Neuropsychopharmacology; 2004 Dec; 29(12):2251-7. PubMed ID: 15354181
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of cognitive functions of juvenile myoclonic epileptic patients by magnetic resonance spectroscopy and neuropsychiatric cognitive tests concurrently.
Cevik N; Koksal A; Dogan VB; Dirican AC; Bayramoglu S; Ozturk M; Baybas S
Neurol Sci; 2016 Apr; 37(4):623-7. PubMed ID: 26603049
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal patterns of β-amyloid deposition in nondemented older adults.
Sojkova J; Zhou Y; An Y; Kraut MA; Ferrucci L; Wong DF; Resnick SM
Arch Neurol; 2011 May; 68(5):644-9. PubMed ID: 21555640
[TBL] [Abstract][Full Text] [Related]
26. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly.
Vemuri P; Lesnick TG; Przybelski SA; Knopman DS; Preboske GM; Kantarci K; Raman MR; Machulda MM; Mielke MM; Lowe VJ; Senjem ML; Gunter JL; Rocca WA; Roberts RO; Petersen RC; Jack CR
Brain; 2015 Mar; 138(Pt 3):761-71. PubMed ID: 25595145
[TBL] [Abstract][Full Text] [Related]
27. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study.
Kantarci K; Jack CR; Xu YC; Campeau NG; O'Brien PC; Smith GE; Ivnik RJ; Boeve BF; Kokmen E; Tangalos EG; Petersen RC
Neurology; 2000 Jul; 55(2):210-7. PubMed ID: 10908893
[TBL] [Abstract][Full Text] [Related]
28. Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.
Targosz-Gajniak MG; Siuda JS; Wicher MM; Banasik TJ; Bujak MA; Augusciak-Duma AM; Opala G
J Neurol Sci; 2013 Dec; 335(1-2):58-63. PubMed ID: 24035276
[TBL] [Abstract][Full Text] [Related]
29. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Byrnes V; Miller A; Lowry D; Hill E; Weinstein C; Alsop D; Lenkinski R; Afdhal NH
J Hepatol; 2012 Mar; 56(3):549-56. PubMed ID: 22027578
[TBL] [Abstract][Full Text] [Related]
30. Cognition, reserve, and amyloid deposition in normal aging.
Rentz DM; Locascio JJ; Becker JA; Moran EK; Eng E; Buckner RL; Sperling RA; Johnson KA
Ann Neurol; 2010 Mar; 67(3):353-64. PubMed ID: 20373347
[TBL] [Abstract][Full Text] [Related]
31. Effect of lifestyle activities on Alzheimer disease biomarkers and cognition.
Vemuri P; Lesnick TG; Przybelski SA; Knopman DS; Roberts RO; Lowe VJ; Kantarci K; Senjem ML; Gunter JL; Boeve BF; Petersen RC; Jack CR
Ann Neurol; 2012 Nov; 72(5):730-8. PubMed ID: 23280791
[TBL] [Abstract][Full Text] [Related]
32. Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.
Winer JR; Maass A; Pressman P; Stiver J; Schonhaut DR; Baker SL; Kramer J; Rabinovici GD; Jagust WJ
JAMA Neurol; 2018 Feb; 75(2):227-235. PubMed ID: 29228071
[TBL] [Abstract][Full Text] [Related]
33. Abnormal levels of brain metabolites may mediate cognitive impairment in stroke-free patients with cerebrovascular risk factors.
Sun D; Zhang J; Fan Y; Liu X; Gao Y; Wu G; Yan Y; Zeng J
Age Ageing; 2014 Sep; 43(5):681-6. PubMed ID: 24614642
[TBL] [Abstract][Full Text] [Related]
34. Face-name associative memory performance is related to amyloid burden in normal elderly.
Rentz DM; Amariglio RE; Becker JA; Frey M; Olson LE; Frishe K; Carmasin J; Maye JE; Johnson KA; Sperling RA
Neuropsychologia; 2011 Jul; 49(9):2776-83. PubMed ID: 21689670
[TBL] [Abstract][Full Text] [Related]
35. Associations between cerebral amyloid and changes in cognitive function and falls risk in subcortical ischemic vascular cognitive impairment.
Dao E; Best JR; Hsiung GR; Sossi V; Jacova C; Tam R; Liu-Ambrose T
BMC Geriatr; 2017 Jun; 17(1):133. PubMed ID: 28659161
[TBL] [Abstract][Full Text] [Related]
36. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients.
Meyerhoff DJ; Bloomer C; Cardenas V; Norman D; Weiner MW; Fein G
Neurology; 1999 Mar; 52(5):995-1003. PubMed ID: 10102419
[TBL] [Abstract][Full Text] [Related]
37. β-Amyloid burden in healthy aging: regional distribution and cognitive consequences.
Rodrigue KM; Kennedy KM; Devous MD; Rieck JR; Hebrank AC; Diaz-Arrastia R; Mathews D; Park DC
Neurology; 2012 Feb; 78(6):387-95. PubMed ID: 22302550
[TBL] [Abstract][Full Text] [Related]
38. APOE genotype modulates proton magnetic resonance spectroscopy metabolites in the aging brain.
Gomar JJ; Gordon ML; Dickinson D; Kingsley PB; Uluğ AM; Keehlisen L; Huet S; Buthorn JJ; Koppel J; Christen E; Conejero-Goldberg C; Davies P; Goldberg TE
Biol Psychiatry; 2014 May; 75(9):686-92. PubMed ID: 23831342
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis of amyloid-cognition relations in cognitively normal older adults.
Hedden T; Oh H; Younger AP; Patel TA
Neurology; 2013 Apr; 80(14):1341-8. PubMed ID: 23547267
[TBL] [Abstract][Full Text] [Related]
40. Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.
Voevodskaya O; Sundgren PC; Strandberg O; Zetterberg H; Minthon L; Blennow K; Wahlund LO; Westman E; Hansson O;
Neurology; 2016 May; 86(19):1754-61. PubMed ID: 27164711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
